Shorter DAPT Tested Following CABG - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Shorter DAPT Tested Following CABG

TOP-CABG compared 3 months vs 12 months of ticagrelor plus aspirin following bypass surgery.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 6 min

Share

  • 1

    Three months of ticagrelor-based dual antiplatelet therapy was noninferior to 12 months for saphenous vein graft occlusion after CABG.

  • 2

    The shorter DAPT duration significantly reduced clinically relevant bleeding compared to the longer duration in selected CABG patients.

  • 3

    The trial included 2,300 patients, with a mean age of 61.5 years, and assessed outcomes at 1 year post-surgery.

  • 4

    Major adverse cardiovascular events were similar between the 3-month and 12-month DAPT groups, but the trial was not powered for these differences.

  • 5

    Findings may not apply to all antiplatelet regimens or patients with specific conditions, limiting generalizability of the results.

Original Source(s)

Shorter DAPT Tested Following CABG

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Case report: Additional Imaging Supports TAPVR Care

A case report shows that advanced cardiac CT and MRI imaging can improve surgical planning and reintervention for patients with infradiaphragmatic total anomalous pulmonary venous return (TAPVR). See what Sebastián Quiñones-Carrasquillo, MD, and co-authors Todd Nowlen, MD and Daniel Velez, MD, recommend for using these advanced diagnostic imaging modalities.

  • by

  • August 12, 2026

  • 6 min
Baptist Health Heart & Vascular Care to Host 43rd Annual Echocardiography and Structural Heart Symposium

Baptist Health South Florida will host the Baptist Health Heart & Vascular Care 43rd Annual Echocardiography and Structural Heart Symposium on Oct. 2-3 at the Loews Coral Gables Hotel.

  • by

  • August 28, 2026

  • 4 min
Heartbeat-powered pacemaker may pave way for self-sustaining devices

A triboelectric nanogenerator–supported pacemaker shows efficacy in a preclinical swine study.